Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review

Introduction. Ocrelizumab is a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, which is approved for the treatment of the relapsing and primary progressive multiple sclerosis (MS). It is extremely rarely associated with late-onset neutropenia (LON), as an...

Full description

Bibliographic Details

Published in:	Srpski Arhiv za Celokupno Lekarstvo
Main Authors:	Jovićević Vanja, Bila Jelena, Mesaroš Šarlota, Pekmezović Tatjana, Drulović Jelena
Format:	Article
Language:	English
Published:	Serbian Medical Society 2022-01-01
Subjects:	late onset neutropenia ocrelizumab multiple sclerosis
Online Access:	http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200042J.pdf